The fracturing of the US drug market’s traditional model is forcing a demand for a strategic bifurcation to maintain profitability, compliance, and patient access in the decade ahead. Building on my ...

Statutory government programs (AMP/ASP, Medicaid best price, IRA, 340B, FSS, Medicare Parts B/D) increasingly define net revenue constraints and shape viable commercial contracting boundaries.

CMS-driven price relief may expand access, but adherence is the key determinant of durable cardiometabolic and weight outcomes in chronic-disease management. Discontinuation rates are high: roughly ...

PBM reform scrutiny of reimbursement, rebate flow, and compensation can shift benefit conditions that determine how manufacturer-funded copay, buy-down, and support programs function at dispensing.

Section 232 introduces a staged tariff regime: 100% default for patented drugs/APIs/KSMs, reduced 20% with approved onshoring plans, and temporary 0% if paired with MFN pricing until 2029. Deadlines ...

Clinician-led engagement outperforms non-clinical call-center models, with “nurse ambassador” programs enabling escalation, symptom recognition, and disease-specific education that supports safer, ...

Medication nonadherence is common and costly, with higher rates in biologics for autoimmune disease (28–52%), reflecting intertwined barriers spanning beliefs, side effects, affordability, and ...

CoT operationalizes channel behavior into system rules that determine customer-specific pricing tiers, discounts, rebates, and distribution pathways, particularly for specialty medicines routed ...

Seven firms were selected for a two-phase FDA program linking new US manufacturing facilities to planned NDA/BLA/ANDA filings or supplements, targeting supply needs and unmet medical needs. Phase 1 ...

Dual BAFF/APRIL blockade targets upstream B-cell survival signaling to reduce production of galactose-deficient IgA1 and anti–Gd-IgA1 autoantibodies driving nephritogenic immune complexes. ORIGIN 3 ...